These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 19188184)
1. Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Speetjens FM; Kuppen PJ; Welters MJ; Essahsah F; Voet van den Brink AM; Lantrua MG; Valentijn AR; Oostendorp J; Fathers LM; Nijman HW; Drijfhout JW; van de Velde CJ; Melief CJ; van der Burg SH Clin Cancer Res; 2009 Feb; 15(3):1086-95. PubMed ID: 19188184 [TBL] [Abstract][Full Text] [Related]
2. Addition of interferon-α to the p53-SLP® vaccine results in increased production of interferon-γ in vaccinated colorectal cancer patients: a phase I/II clinical trial. Zeestraten EC; Speetjens FM; Welters MJ; Saadatmand S; Stynenbosch LF; Jongen R; Kapiteijn E; Gelderblom H; Nijman HW; Valentijn AR; Oostendorp J; Fathers LM; Drijfhout JW; van de Velde CJ; Kuppen PJ; van der Burg SH; Melief CJ Int J Cancer; 2013 Apr; 132(7):1581-91. PubMed ID: 22948952 [TBL] [Abstract][Full Text] [Related]
3. Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. Leffers N; Lambeck AJ; Gooden MJ; Hoogeboom BN; Wolf R; Hamming IE; Hepkema BG; Willemse PH; Molmans BH; Hollema H; Drijfhout JW; Sluiter WJ; Valentijn AR; Fathers LM; Oostendorp J; van der Zee AG; Melief CJ; van der Burg SH; Daemen T; Nijman HW Int J Cancer; 2009 Nov; 125(9):2104-13. PubMed ID: 19621448 [TBL] [Abstract][Full Text] [Related]
4. Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study. Vermeij R; Leffers N; Hoogeboom BN; Hamming IL; Wolf R; Reyners AK; Molmans BH; Hollema H; Bart J; Drijfhout JW; Oostendorp J; van der Zee AG; Melief CJ; van der Burg SH; Daemen T; Nijman HW Int J Cancer; 2012 Sep; 131(5):E670-80. PubMed ID: 22139992 [TBL] [Abstract][Full Text] [Related]
5. Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine. van der Burg SH; Menon AG; Redeker A; Bonnet MC; Drijfhout JW; Tollenaar RA; van de Velde CJ; Moingeon P; Kuppen PJ; Offringa R; Melief CJ Clin Cancer Res; 2002 May; 8(5):1019-27. PubMed ID: 12006514 [TBL] [Abstract][Full Text] [Related]
6. Long-term clinical and immunological effects of p53-SLP® vaccine in patients with ovarian cancer. Leffers N; Vermeij R; Hoogeboom BN; Schulze UR; Wolf R; Hamming IE; van der Zee AG; Melief KJ; van der Burg SH; Daemen T; Nijman HW Int J Cancer; 2012 Jan; 130(1):105-12. PubMed ID: 21328579 [TBL] [Abstract][Full Text] [Related]
7. Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer. Aruga A; Takeshita N; Kotera Y; Okuyama R; Matsushita N; Ohta T; Takeda K; Yamamoto M Clin Cancer Res; 2013 Apr; 19(8):2224-31. PubMed ID: 23479678 [TBL] [Abstract][Full Text] [Related]
8. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269 [TBL] [Abstract][Full Text] [Related]
9. Magnitude and polarization of P53-specific T-helper immunity in connection to leukocyte infiltration of colorectal tumors. van der Burg SH; Menon AG; Redeker A; Franken KL; Drijfhout JW; Tollenaar RA; Hartgrink HH; van de Velde CJ; Kuppen PJ; Melief CJ; Offringa R Int J Cancer; 2003 Nov; 107(3):425-33. PubMed ID: 14506743 [TBL] [Abstract][Full Text] [Related]
10. Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2. Svane IM; Pedersen AE; Nikolajsen K; Zocca MB Vaccine; 2008 Aug; 26(36):4716-24. PubMed ID: 18616968 [TBL] [Abstract][Full Text] [Related]
11. Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients. Snook AE; Baybutt TR; Xiang B; Abraham TS; Flickinger JC; Hyslop T; Zhan T; Kraft WK; Sato T; Waldman SA J Immunother Cancer; 2019 Apr; 7(1):104. PubMed ID: 31010434 [TBL] [Abstract][Full Text] [Related]
12. Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer. Matsushita N; Aruga A; Inoue Y; Kotera Y; Takeda K; Yamamoto M Oncol Rep; 2013 Mar; 29(3):951-9. PubMed ID: 23314271 [TBL] [Abstract][Full Text] [Related]
13. Phase I dendritic cell p53 peptide vaccine for head and neck cancer. Schuler PJ; Harasymczuk M; Visus C; Deleo A; Trivedi S; Lei Y; Argiris A; Gooding W; Butterfield LH; Whiteside TL; Ferris RL Clin Cancer Res; 2014 May; 20(9):2433-44. PubMed ID: 24583792 [TBL] [Abstract][Full Text] [Related]
14. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. Kavanagh B; Ko A; Venook A; Margolin K; Zeh H; Lotze M; Schillinger B; Liu W; Lu Y; Mitsky P; Schilling M; Bercovici N; Loudovaris M; Guillermo R; Lee SM; Bender J; Mills B; Fong L J Immunother; 2007 Oct; 30(7):762-72. PubMed ID: 17893568 [TBL] [Abstract][Full Text] [Related]
15. A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. Kakimi K; Isobe M; Uenaka A; Wada H; Sato E; Doki Y; Nakajima J; Seto Y; Yamatsuji T; Naomoto Y; Shiraishi K; Takigawa N; Kiura K; Tsuji K; Iwatsuki K; Oka M; Pan L; Hoffman EW; Old LJ; Nakayama E Int J Cancer; 2011 Dec; 129(12):2836-46. PubMed ID: 21448901 [TBL] [Abstract][Full Text] [Related]
16. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs. Nakamura M; Iwahashi M; Nakamori M; Ueda K; Ojima T; Naka T; Ishida K; Yamaue H Oncology; 2005; 68(2-3):163-70. PubMed ID: 16006753 [TBL] [Abstract][Full Text] [Related]
17. Phase II study of personalized peptide vaccination for previously treated advanced colorectal cancer. Kibe S; Yutani S; Motoyama S; Nomura T; Tanaka N; Kawahara A; Yamaguchi T; Matsueda S; Komatsu N; Miura M; Hinai Y; Hattori S; Yamada A; Kage M; Itoh K; Akagi Y; Sasada T Cancer Immunol Res; 2014 Dec; 2(12):1154-62. PubMed ID: 25351849 [TBL] [Abstract][Full Text] [Related]
18. A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma. Uemura H; Fujimoto K; Tanaka M; Yoshikawa M; Hirao Y; Uejima S; Yoshikawa K; Itoh K Clin Cancer Res; 2006 Mar; 12(6):1768-75. PubMed ID: 16551861 [TBL] [Abstract][Full Text] [Related]
19. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Davila E; Kennedy R; Celis E Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660 [TBL] [Abstract][Full Text] [Related]
20. A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients. Sato Y; Maeda Y; Shomura H; Sasatomi T; Takahashi M; Une Y; Kondo M; Shinohara T; Hida N; Katagiri K; Sato K; Sato M; Yamada A; Yamana H; Harada M; Itoh K; Todo S Br J Cancer; 2004 Apr; 90(7):1334-42. PubMed ID: 15054451 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]